Roche Holding : Q1 2020 postview: the currently favourable momentum should continue
>As we had anticipated, guidance is unchanged despite the pandemic - As indicated in our hierarchy for big pharma in the face of COVID-19 (studies published on 10 and 31 March), Roche is our Top Pick. The Q1 publication lends weight to our view since the group is maintaining its full-year guidance (sales and EPS growth in the low to mid single digits, excluding forex effects). The group has encountered no production stoppages and, as we indicated, with cancer patient...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.